GlassScriptPhysician profile
William J Woods
NPI 1730117193
$9,907.84
in general payments reported to CMS, 2019-2025
42 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $1,369 · 2021: $1,743 · 2022: $1,409 · 2023: $1,690 · 2024: $1,578 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,251.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,086.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $976.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $848.08 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $630.71 | 2019-2025 | |
| Astellas Pharma US INC | $539.06 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.09 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $437.71 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.49 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Amarin Pharma, INC. | $357.23 | 2019-2022 | |
| Esperion Therapeutics, INC. | $324.85 | 2020-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $287.24 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbott Laboratories | $214.48 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $172.18 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $159.33 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.